Synektik Pharma sp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2011-09-09
Share capital
10,050.00 PLN
Average employment (people)
54 (2025)
Activity description

Synektik Pharma Sp. z o.o. is part of the Synektik Group. The Group provides medical facilities with medical technologies, robotics, radiopharmaceuticals and IT solutions.

Registered address
ul. Józefa Piusa Dziekońskiego 3, 00-728 Warszawa, Poland
Branches
  • al. Roździeńskiego 188c, 40-203 Katowice
  • ul. Szaserów 128, 04-349 Warszawa
  • ul. Artwińskiego 3, 25-734 Kielce
  • ul. Keramzytowa 16, 96-320 Mszczonów
Email
Phone
Social media
Electronic delivery address
AE:PL-61568-32596-VUFGS-34

Financials

Revenue history (in m)

From the notes

Profit allocationDividend and reserves
Loans and borrowings$0
Capital expenditure$287,105
Planned capital expenditure (next year)$376,695
Foreign sales2.34% of revenue ($303,388)
Revenue structureSprzedaż radiofarmaceutyków – produkty i usługi

Filing timeliness

Financial statements were filed on time, on average 47 days early. 5 of 6 audited by a statutory auditor.

  • 202530/03/2026
  • 202417/03/2025
  • 202319/02/2024
  • 202227/03/2023
  • 202125/02/2022
  • 202026/03/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Sector · Manufacturing3,570 / 24,603
Top 15%
City · Warszawa3,142 / 56,857
Top 5.5%
Voivodeship · Mazowieckie4,328 / 77,058
Top 5.6%
Country · Poland15,286 / 297,566
Top 5.1%

Results vs industry

Revenue
This companyUSD 13.22mMedianUSD 913.43kAverageUSD 25.83m
Net profit
This companyUSD 2.01mMedianUSD 14.22kAverageUSD 2.77m
Operating costs
This companyUSD 10.17mMedianUSD 846.99kAverageUSD 21.38m
Assets
This companyUSD 12.07mMedianUSD 897.46kAverageUSD 31.54m

Offer

  • Surgical robots
  • Medical imaging equipment
  • Radiopharmaceuticals
  • Medical software
  • CO2 injectors
  • Histotripsy systems
  • Endometrial ablation kits
  • Densitometers

Websites

The site is available in: Polish, English and cz.

  • synektik.com.plTechnologie medyczne i innowacje – Synektik
    WordPress 7.1Google AnalyticsGoogle Tag ManagerYoast SEOCloudflare

Public procurement

73 tenders recorded as contractor: 34 national ($4,387,779) and 39 EU ($15,707,163).

SubjectAmount
Supply of medicinal products and radiopharmaceuticals
$526.9K
Emergency purchase of 18F-FDG radiopharmaceutical for PET examinations for Zakład Medycyny Nuklearnej z Ośrodkiem PET Świętokrzyskie Centrum Onkologii in Kielce. IZP.2411.197.2026.AJ
–
Supply of radioisotope materials
$21,340

Job offers

The company lists 6 job openings on its own careers page: synektik.com.pl/category/kariera.

Position
Debt collection assistant
Sales director (F/M)
Regional Sales Director Da Vinci (F/M)

Authorized Representatives

Przemysław Bolesław Kozanecki age 57 – President of the Management Board

Manner of representation

In the case of a one-person management board, each member of the management board acting independently. In the case of a multi-member management board, the President of the Management Board independently, or two members of the management board acting jointly, or one member of the management board acting jointly with a commercial proxy.

Ownership

OwnerSharesShare valueStake
201$2,714.75100%

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2011-09-14.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Land (incl. perpetual usufruct)
$98,810
Buildings and premises
$1.5M

Public aid

7 public aid cases recorded, with a total value of $870,982.

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$11,158
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$11,568
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$11,060

European Funds

ProjectEU co-financing
Development of Synektik Pharma’s research and development facilities to develop new specialized radiopharmaceuticals for targeted oncological and neurological diagnostics using positron emission tomography (PET)
$428.7K
Market launch of a new radiopharmaceutical, 18F-fluorothymidine (FLT), for targeted cancer diagnostics and assessment of treatment progress.
$227.6K

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Intimex sp. z o.o. + limited partnership
Nova Group A. Chmielewski sp. k.
Polymed Polska sp. z o.o.
Timko sp. z o.o.
P.A.D. Technologies Ltd sp. z o.o.
Solve Medical sp. z o.o.
Binatural Krystosiak sp. k.
Shar-POL sp. z o.o.
Meditrade Poland sp. z o.o.
Medico Systems sp. z o.o.

Change history

DateEvent
2021-08-12Address change
2018-08-24Share capital reduction
2018-07-04Share capital increase
2018-05-10Address change
2018-05-10Name change

FAQ

Last updated: 2026-10-07